Evidence map›Paper›PMID 41996548›Full record

ArticleChembiochem : a European journal of chemical biology2026

Accessing New Phenanthroline-Oxazine Scaffolds as Copper-Dependent DNA Damaging Probes.

Rebecca Lynn, Alex Gibney, Eva Delahunt, Stephen MacDonald-Brown, Carlos Lence, Miles Kenny, Matt Allen, Ravil Khaybullin, Iva Lukac, Andrew Jordan and 1 more

Abstract read
In one paragraph

Article in Chembiochem : a European journal of chemical biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Rebecca LynnResearch Ireland Centre for Pharmaceuticals, School of Chemical Sciences, Dublin City University, Dublin, Ireland.
Alex GibneyResearch Ireland Centre for Pharmaceuticals, School of Chemical Sciences, Dublin City University, Dublin, Ireland.ORCID https://orcid.org/0000-0001-8541-8796
Eva DelahuntResearch Ireland Centre for Pharmaceuticals, School of Chemical Sciences, Dublin City University, Dublin, Ireland.ORCID https://orcid.org/0009-0001-3540-2814
Stephen MacDonald-BrownCharnwood Discovery, Charnwood Campus, Loughborough, UK.
Carlos LenceCharnwood Discovery, Charnwood Campus, Loughborough, UK.
Miles KennyCharnwood Discovery, Charnwood Campus, Loughborough, UK.
Matt AllenCharnwood Discovery, Charnwood Campus, Loughborough, UK.
Ravil KhaybullinCharnwood Discovery, Charnwood Campus, Loughborough, UK.
Iva LukacCharnwood Discovery, Charnwood Campus, Loughborough, UK.
Andrew JordanCharnwood Discovery, Charnwood Campus, Loughborough, UK.
Andrew KellettResearch Ireland Centre for Pharmaceuticals, School of Chemical Sciences, Dublin City University, Dublin, Ireland.ORCID https://orcid.org/0000-0002-8947-1401

Funding

HORIZON EUROPE Marie Sklodowska-Curie Actions 861381Irish Research Council IRCLA/2022/3815Novo Nordisk Fonden NNF19OC0056845Science Foundation Ireland 12/RC/2275_P2
6 · The paper itself

Abstract

1,10-Phenanthroline (phen) is a versatile ligand commonly used in coordination chemistry, with particular interest in its ability to promote DNA binding and damage when coordinated with transition metals. Structural modifications of phen modulate the recognition and reactivity of the associated complexes at the nucleic acid interface. A promising new modification of phen stems from the incorporation of amino acid derivatives at the 5- and 6-positions leading to phenanthroline-oxazine scaffolds, which improve the pharmacokinetic and pharmacodynamic properties of resultant complexes. However, a limited number of phenanthroline-oxazine (PO) scaffolds have been reported and accessing new natural amino acid derivatives has, thus far, been synthetically intractable. Herein, we advance the synthetic conditions required for accessing new POs. We identified the type of amino acid substrate coupled with solvent selection and reaction temperature were the main influencing parameters for accessing new PO scaffolds. In total, eleven new PO ligands were successfully synthesized, purified, and characterized. The new scaffolds were then examined for their Cu-dependent DNA binding and damaging profiles and we correlate structure-activity relationships to specific PO modifications.

Indexed as

CopperDNADNA DamageOxazinesPhenanthrolinesLigands1,10-phenanthrolineCopperDNALigandsOxazinesPhenanthrolinesamino acidchemical nucleasecopperDNA bindingoxazine

Identifiers

PMID41996548
PMCPMC13089940

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.